colorado blood cancer institute

What colorado blood cancer institute does

Colorado Blood Cancer Institute (CBCI) is a Denver-based hematology and cellular therapy center providing diagnosis, treatment, and transplant services for blood cancers and related disorders. Founded in 1996 as part of Presbyterian/St. Luke's Medical Center, CBCI operates within the HCA Healthcare network as the Sarah Cannon Cancer Institute at P/SL and is accredited by the Foundation for Accreditation of Cellular Therapies (FACT). The institute runs disease-specific programs in Multiple Myeloma, Leukemia, and Lymphoma, supplemented by an autoimmune-disease program, and serves patients across Colorado, New Mexico, Montana, and Wyoming via physician referrals and telehealth. Over its 30-year history, CBCI has performed more than 5,000 blood and marrow transplant procedures, including 1,000+ myeloma transplants, by a physician team carrying 150+ years of combined blood-cancer experience (co-directed by Dr. Jeffrey Matous and Dr. Tara Gregory).

The institute's underlying technology platform is its FACT-accredited cellular-therapy program, delivering autologous and allogeneic hematopoietic stem cell transplantation supported by apheresis-based stem cell collection, bone-marrow harvest, cryopreservation, and transplantation workflows. Adjacent modalities include CAR T-cell therapy, chemotherapy, immunotherapy, radiation therapy, infusion therapy, diagnostic imaging, and laboratory testing. CBCI is also a member of the Sarah Cannon Research Institute, providing access to clinical trials whose outcomes have contributed to FDA-approved cancer therapies. Patient engagement is supported by a secure patient portal, telehealth visits, and patient-education resources.

Revenue is generated through professional services rendered to patients under standard insurance reimbursement, including consultations, chemotherapy, immunotherapy, stem-cell transplants, radiation therapy, infusion therapy, and diagnostics, with no publicly disclosed pricing. Patient acquisition runs predominantly through community-physician referrals across the four-state catchment, supplemented by direct telephone scheduling and Sarah Cannon Research Institute clinical-trial enrollment. CBCI does not operate as an independent commercial entity; its financial profile is consolidated within HCA Healthcare, Inc. (NYSE: HCA), and no separate facility-level revenue is disclosed.

Name

colorado blood cancer institute

Legal name

Colorado Blood Cancer Institute

Website

https://bloodcancerinstitute.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Colorado Blood Cancer Institute is a Denver-based, FACT-accredited hematology and cellular therapy center delivering blood and marrow transplantation, CAR T-cell therapy, and disease-specific oncology care to patients across Colorado, New Mexico, Montana, and Wyoming within the HCA Healthcare network.

Ownership category

akta.pro rank

Product category

Hematology and Oncology Services

NAICS

Offices of Physicians (62111), Ambulatory Health Care Services (621), Medical and Diagnostic Laboratories (62151)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI)

akta.pro secondary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

• Hematology services
• Stem cell transplantation
• Blood cancer treatment
• Cellular therapy
• Bone marrow transplant

Headquarters

HQ city

Denver

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Services Revenue: Healthcare services revenue from treating patients with blood cancers, including consultations, diagnostic services, chemotherapy, radiation therapy, infusion therapy, stem cell transplants, and related treatments. Revenue generated through insurance reimbursement and patient payments.
2. Clinical Trials Research: Participation in clinical trials through partnership with HCA Healthcare Sarah Cannon Cancer Network, providing access to innovative treatments and research funding.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Colorado Blood Cancer Institute (CBCI) is a specialty hematology practice that diagnoses and treats blood cancers and related disorders, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. The institute runs a high-volume blood and marrow transplant program and delivers cellular therapies such as CAR T-cell therapy. It operates as part of the Sarah Cannon transplant network within HCA Healthcare, providing inpatient and outpatient hematology care at Presbyterian/St. Luke's Medical Center in Denver.

Product overview

Colorado Blood Cancer Institute (CBCI) is a comprehensive blood and marrow transplant program providing treatment for blood cancers and related disorders. The institution operates as a unified care platform centered on its transplant and cellular therapy services, supported by disease-specific programs for Multiple Myeloma, Leukemia, and Lymphoma. Core treatment services include CAR T-Cell therapy, chemotherapy, infusion therapy, radiation therapy, and clinical trials. Support services include diagnostics/laboratory, imaging, nutrition, and telehealth visits. A patient portal provides secure access to medical records and provider communication. CBCI is part of the Sarah Cannon Cancer Institute at Presbyterian/St. Luke's Medical Center and is accredited by FACT.

Differentiator

Problem solved

Functional benefit

Products and services

• Blood and Marrow Transplant Program

Quantifiable outcome

• 5,000+ transplant procedures performed
• +3 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• HCA Healthcare Sarah Cannon Cancer NetworkcoreStrategic or Co-development PartnerPartnership with HCA Healthcare Sarah Cannon Cancer Network provides access to an expansive network advancing therapies for effective cancer treatment. Through this partnership, CBCI participates in clinical trials that have contributed to pivotal research leading to FDA-approved cancer therapies. The network connects CBCI with other cancer centers for research collaboration and treatment protocols.
• Sarah Cannon Research Institute (SCRI)coreStrategic or Co-development PartnerCBCI is a member of Sarah Cannon Research Institute, a unique partnership dedicated to making a difference in patients' lives and advancing novel therapies. This provides access to cutting-edge clinical trials and research protocols.
• Presbyterian/St. Luke's Medical CentercoreStrategic or Co-development PartnerCBCI is part of the Sarah Cannon Cancer Institute at Presbyterian/St. Luke's Medical Center, providing the facility and infrastructure for comprehensive blood cancer treatment and stem cell transplantation services.
• HCA HealthcarecoreStrategic or Co-development PartnerParent organization HCA Healthcare provides operational infrastructure, resources, and network connectivity enabling CBCI to participate in the broader HCA Healthcare cancer care network.
• Be The Match RegistryminorStrategic or Co-development PartnerPartnership with Be The Match Registry and Colorado Marrow Donor Program to facilitate stem cell and marrow transplants and recruit potential donors. Helps patients find compatible unrelated donors for transplantation.
• Leukemia & Lymphoma SocietyminorOthersResource partner providing patient education and support for leukemia patients. Listed as a resource for patients seeking additional information about their condition and support services.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dana-Farber Cancer Institute: Harvard-affiliated cancer center with one of the largest BMT programs in the Northeast. Directly comparable to CBCI for leukemia, myeloma, and lymphoma treatment with strong clinical trial pipelines.
• Mayo Clinic Comprehensive Cancer Center: Multispecialty academic medical center with a major hematology and BMT program across its Arizona, Florida, and Rochester campuses. Directly comparable for high-acuity blood cancer treatment and cellular therapy.
• Vanderbilt-Ingram Cancer Center: NCI-designated comprehensive cancer center with a major hematology-oncology and stem cell transplant program. Directly comparable to CBCI for leukemia, lymphoma, myeloma treatment and clinical trial access.
• Fred Hutchinson Cancer Center: Pioneer of bone marrow transplantation and one of the most renowned BMT programs in the world. Directly comparable to CBCI for allogeneic and autologous transplant, immunotherapy, and clinical trial access.
• H. Lee Moffitt Cancer Center & Research Institute: National Cancer Institute-designated comprehensive cancer center with a large BMT and cellular immunotherapy program. Directly comparable to CBCI for blood cancer and stem cell transplant services.
• MD Anderson Cancer Center: The largest dedicated cancer center in the U.S. and a global leader in BMT and CAR T-cell therapy. Directly comparable to CBCI as a high-volume blood cancer and stem cell transplant program serving complex hematologic malignancy cases.
• Memorial Sloan Kettering Cancer Center: Premier U.S. cancer center with a large hematology-oncology and BMT service. Directly comparable to CBCI for blood cancer treatment, CAR T-cell therapy, and stem cell transplantation.
• City of Hope Comprehensive Cancer Center: Leading U.S. center for BMT and CAR T-cell therapy with one of the highest transplant volumes nationally. Directly comparable to CBCI for autologous/allogeneic transplant and hematology-oncology specialty care.
• Stanford Medicine — Stanford Cancer Institute: Academic comprehensive cancer center with a strong BMT and CAR T-cell therapy program. Directly comparable to CBCI for hematologic malignancy treatment, cellular therapy, and clinical trial access on the West Coast.

Broad incumbents

• Sarah Cannon Cancer Institute: Parent network for CBCI's HCA Healthcare cancer programs, operating cancer care across a national footprint. Comparable as the broader platform providing clinical trial access, network reach, and brand that CBCI operates within.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/colorado-blood-cancer-institute

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about colorado blood cancer institute